Skip to content

A Study on the Preference of Risperidone Dosage Forms

A Study on the Preference of Risperidone Dosage Forms

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06657430
Enrollment
1000
Registered
2024-10-24
Start date
2024-09-19
Completion date
2025-02-28
Last updated
2024-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder, Bipolar Affective Disorder, Conduct Disorder, Mental Retardation, Schizophrenia

Keywords

risperidone, patch, cross-sectional study, preference

Brief summary

This study aimed to understand patients' needs and preferences for antipsychotic dosage forms.

Detailed description

This study aims to understand patients' needs and preferences for antipsychotic dosage forms and to clarify the clinical value of patch-form antipsychotics.

Interventions

None listed

Sponsors

Shanghai Mental Health Center
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with schizophrenia, bipolar disorder, autism spectrum disorder, mental retardation or their primary caregivers who voluntarily participate in the study.

Exclusion criteria

* Have difficulty reading and understanding Chinese or refuse to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients (and their caregivers) who prefer risperidone patch-form medicinethrough study completion, an average of 6 monthsThe proportion of patients (and their caregivers) who preferred risperidone patch among the respondents in this study

Secondary

MeasureTime frameDescription
Factors related to patients' preference for risperidone patch-form medicinesthrough study completion, an average of 6 monthsPatients' evaluation of the importance of each advantage of risperidone patch in a self-made questionnaire (5-point Likert scale score)

Countries

China

Contacts

Primary ContactLan Luo, Doctor of Medicine
lan-luo@foxmail.com+8618516544150

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026